Your Global Health Resource

 July 23, 2025

Congestive heart failure (CHF) is a complex clinical syndrome characterized by the heart’s inability to pump or fill adequately, resulting in insufficient tissue perfusion and fluid accumulation in the extracellular space. It is a leading cause of hospitalization and cardiovascular mortality worldwide, especially among older adults. Proper management requires a comprehensive approach encompassing pathophysiology, etiology, diagnosis, treatment, and follow-up.

CHF arises when a structural or functional myocardial abnormality impairs adequate ventricular filling or ejection. Consequently:

• Cardiac output (CO) is reduced.
   
• Intracavitary pressures (atrial and ventricular) increase.
   
• Neurohormonal compensatory mechanisms are activated: sympathetic nervous system, renin-angiotensin-aldosterone system (RAAS), vasopressin.
   
• Sodium and water retention occur, leading to extracellular volume expansion, pulmonary and peripheral edema.
   
• The heart attempts compensation via ventricular remodeling, myocardial hypertrophy, and tachycardia—but these mechanisms are unsustainable and ultimately worsen the failure.
   

According to left ventricular ejection fraction (LVEF):

• HFrEF (reduced): LVEF < 40%
   
• HFmrEF (mid-range): LVEF 40–49%
   
• HFpEF (preserved): LVEF ≥ 50%
   

According to hemodynamic pattern:

• Left-sided failure: predominant pulmonary congestion
   
• Right-sided failure: systemic congestion
   
• Biventricular failure: global compromise
   

According to evolution time:

• Acute: rapid onset
   
• Chronic: stable or with episodes of decompensation
   

Symptoms:

• Exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea
   
• Fatigue, weakness, exercise intolerance
   
• Peripheral edema
   
• Weight gain from fluid retention
   
• Ascites, abdominal fullness
   

Signs:

• Basal crackles
   
• Elevated jugular venous pressure
   
• Hepatomegaly, hepatojugular reflux
   
• Malleolar and sacral edema
   
• S3 gallop (systolic) or S4 (diastolic)
   
• Cardiomegaly
   

1. Arterial Hypertension (HTN)
   Pressure overload → concentric left ventricular hypertrophy → diastolic dysfunction → HFpEF. May progress to systolic dysfunction.
    
2. Ischemic Heart Disease / Myocardial Infarction
   Myocardial necrosis ↓ contractility → ventricular remodeling and dilation → systolic dysfunction → HFrEF. Leading cause in developed countries.
    
3. Valvular Diseases
    
   • Aortic/Mitral stenosis: pressure overload → concentric hypertrophy → diastolic dysfunction.
      
   • Aortic/Mitral regurgitation: volume overload → ventricular dilation → systolic dysfunction.
      

1. Cardiomyopathies
    
   • Dilated: reduced global contractility
      
   • Hypertrophic: outflow obstruction, diastolic dysfunction
      
   • Restrictive (e.g., amyloidosis): stiff ventricles, impaired filling
      

1. Constrictive Pericarditis
   Pericardial fibrosis limits diastolic ventricular expansion → severe systemic venous congestion without significant dilation.
    
2. Cardiac Amyloidosis
   Extracellular amyloid deposition → restrictive cardiomyopathy → CHF with preserved EF and high filling pressures. Poor prognosis.
    
3. Elevated Ferritin / Hemochromatosis
   Iron overload in myocardium → systolic or restrictive dysfunction → CHF.
    
4. Pulmonary Hypertension
   Increased RV afterload → RV hypertrophy → RV failure → hepatic and peripheral congestion.
    
5. Portal Hypertension
   Chronic splanchnic hyperemia → high-output state → eventual cardiac decompensation.
    
6. Chronic Pulmonary Embolism
   Progressive pulmonary vascular obstruction → secondary pulmonary hypertension → RV dysfunction.
    
7. Septal Defects (ASD/VSD)
   Left-to-right shunts → RV volume overload → RV hypertrophy, dilation, failure. Severe cases → Eisenmenger syndrome.
    

History and Physical Exam
Clinical suspicion based on dyspnea, orthopnea, edema, exercise intolerance. NYHA functional classification is useful for follow-up.

Complementary Tests

• BNP / NT-proBNP: elevated in volume/pressure overload; diagnostic and monitoring value
   
• ECG: shows hypertrophy, ischemia, arrhythmias
   
• Chest X-ray: cardiomegaly, Kerley B lines, interstitial edema
   
• Echocardiogram: essential to assess EF, valvular function, hypertrophy, estimated pressures
   
• Labs: renal/liver function, electrolytes, HbA1c, TSH, ferritin
   
• Cardiac catheterization: for selected cases (coronary disease or precise hemodynamic evaluation)
   

• Oxygen if hypoxic
   
• IV diuretics (furosemide)
   
• Vasodilators (nitroglycerin if BP allows)
   
• Inotropes (dobutamine, milrinone) in hypoperfusion
   
• Intensive monitoring if severe pulmonary edema or hypotension
   

1. General Measures:
    
   • Sodium restriction (<2 g/day)
      
   • Supervised physical activity
      
   • Control of BP, glucose, and lipids
      
   • Avoid NSAIDs and alcohol
      

1. Pharmacologic Treatment
    

In HFrEF:

• ACEIs / ARBs or ARNI (sacubitril-valsartan)
   
• Beta-blockers (carvedilol, bisoprolol, metoprolol succinate)
   
• Aldosterone antagonists (spironolactone)
   
• SGLT2 inhibitors (dapagliflozin, empagliflozin)
   
• Loop diuretics (for symptoms)
   
• Hydralazine + nitrates (in African Americans or ACEI-intolerant patients)
   

In HFpEF:

• Strict BP, HR, and volume control
   
• SGLT2 inhibitors show promise
   
• Symptomatic use of diuretics
   

1. Natural Treatments and Diet
    

• DASH diet: low sodium, high potassium/magnesium
   
• Stress and sleep management
   
• Gradual physical activity under supervision
   
• Supplements with limited evidence: CoQ10, omega-3, L-carnitine
   

• ICD (Implantable Cardioverter-Defibrillator): LVEF <35% with NYHA II–III despite optimal therapy
   
• CRT (Cardiac Resynchronization Therapy): LVEF <35% + QRS ≥150 ms with LBBB
   
• Heart transplant: end-stage CHF, age <65, no contraindications
   
• LVAD (Left Ventricular Assist Device): bridge to transplant or destination therapy in non-transplant candidates
   

ParameterFrequencyPurposeClinical (weight, symptoms)Daily / visitsCongestion controlLabs (renal function, electrolytes, BNP)Every 3–6 monthsTreatment adjustmentECGEvery 6–12 monthsArrhythmia monitoringEchocardiogramEvery 6–12 monthsEF, valvular assessment6-minute walk testAs indicatedFunctional capacity  

Prognosis depends on CHF type, etiology, NYHA class, and treatment response. Poor prognostic indicators include LVEF <20%, NYHA class IV, frequent hospitalizations, hyponatremia, cachexia, and persistently elevated BNP.

**NYHA Class1-Year Survival**I>90%II85%III60–75%IV30–50% 

Optimal therapeutic interventions have significantly improved survival over the past decades.

Congestive heart failure is a complex syndrome with multiple causes and clinical presentations. Its management demands precise diagnosis, personalized treatment, and continuous monitoring. The integration of modern pharmacologic therapies, device support, lifestyle changes, and a multidisciplinary approach offers a real opportunity to improve both the quality and duration of life for these patients.

RaulAyalaMD
@MyDoctorOnCallcom